ClinicalTrials.gg
RecruitingNCT06051409Updated Apr 30, 2026

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

A Phase 3 interventional study of Olverembatinib and Investigator's choice of TKI in Ph+ ALL and Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, sponsored by Ascentage Pharma Group Inc.. Recruiting at 90 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Ascentage Pharma Group Inc. (part of Ascentage Pharma Group International) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing olverembatinib in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 10 open to participants now, 10 under way, 2 of them phase 3. olverembatinib · Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Planned enrollment
Largest of 11
350 · median 60
Started
2023
with 1 other
Phase 3
2 of 11
2 open now
Registered
3rd of 11
by date
Lead sponsor
1 of 11
Ascentage Pharma Group Inc.

Among the 11 studies testing olverembatinib in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one has the largest planned enrollment, is one of 2 that started in 2023, is one of 2 in phase 3, and was the 3rd registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 474 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

10 of the 11 studies testing olverembatinib in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About olverembatinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 371 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 258 (70%) stop at 75 or younger; 248 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing olverembatinib in Precursor Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

A global multicenter, open-label, randomized and registrational Phase 3 study to evaluate efficacy and safety of olverembatinib combined with chemotherapy versus investigator's choice of tyrosine kinase inhibitor (TKI) combined with chemotherapy in subjects with newly-diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL).

Read the detailed description

Comparing efficacy and safety of olverembatinib in combination with chemotherapy (investigational arm) vs. investigator's choice of TKI in combination with chemotherapy (control arm).

03

Conditions studied

  • Ph+ ALL
  • Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

Keywords

  • Ph+ ALL
  • Olverembatinib
  • Acute lymphoblastic leukemia
  • Bcr-Abl Tyrosine Kinase
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Newly diagnosed Philadelphia chromosome-positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
  2. Expected survival of at least 3 months
  3. ≤ 2
  4. Adequate organ function

Exclusion criteria

Exclusion Criteria:

  1. A history of chronic myeloid leukemia (CML)
  2. Clinical manifestations of central nervous system (CNS) leukemia or ALL extramedullary infiltration, except lymphadenopathy or hepatosplenomegaly
  3. Previous or current clinical CNS diseases
  4. diseases that may involve the CNS
  5. Use of therapeutic doses of anticoagulants and/or antiplatelet agents; low doses of anticoagulants or antiplatelet agents are allowed
  6. Use a therapeutic drug that has drug interaction with the drug due to other diseases within 7 days or within 5 half-lives (whichever is shorter) prior to the first receipt of the investigational drug
  7. Uncontrolled heart diseases
  8. Any venous thromboembolism in the 6 months prior to randomization, including but not limited to deep vein thrombosis (DVT) or pulmonary embolism
  9. Use of prohibited drugs
  10. Disease or medical condition that is unstable or may affect its safety or compliance with the study
  11. Use of medications known to cause prolonged
  12. Active infections requiring systemic treatment
  13. Disease that severely affects the oral administration and absorption of drugs, or an active gastrointestinal ulcer
  14. to the use of
  15. Bleeding disorders unrelated to ALL
  16. Plan to undergo major surgery
  17. Allergy to drug ingredients, , or their analogues in the study
  18. Female subjects who are pregnant or breastfeeding or expect to become pregnant during the study period
  19. Other malignant tumors within 2 years
  20. Any symptom or illness that may interfere with the evaluation of the efficacy and safety of the investigational drug, or any other condition or condition that is not appropriate for participation in the study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
350 participants (estimated)

Study arms

  • Experimental
    Olverembatinib

    Olverembatinib in combination with chemotherapy

    Drug: Olverembatinib

  • Active comparator
    Investigator's choice of TKI

    Investigator's choice of TKI in combination with chemotherapy

    Drug: Investigator's choice of TKI

Interventions

  • Oral (PO) once every other day (QOD).

  • DrugInvestigator's choice of TKI

    Oral (PO) once daily (QD).

06

What researchers measure

Primary outcomes

  1. Minimal Residual Disease Negative CR Rate

    The minimal residual disease negative CR rate of olverembatinib combined with chemotherapy versus investigator's choice of TKI combined with chemotherapy in subjects with newly diagnosed Ph+ALL.

    Time frame: Cycle 1 to Cycle 3 (each cycle is 28 days)

Secondary outcomes

  1. Event-free Survival (EFS)

    EFS is defined as the time from study randomization to the date of treatment failure (ITF), relapse from CR, or death from any cause, whichever comes first.

    Time frame: Baseline up to 3 to 6 years

  2. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.

    According to CTCAE v5.0, the number and frequency of adverse events of test drug will be assessed.

    Time frame: Through study completion (approximately 2 years)

  3. Plasma concentrations of olverembatinib

    Blood samples will be collected to measure the plasma concentration of olverembatinib.

    Time frame: Cycle 1 to Cycle 3 (each cycle is 28 days)

  4. FACT-Leu (Functional Assessment of Cancer Therapy - Leukemia) Score

    To evaluate health-related Quality of Life (HR-QoL) in patients treated with olverembatinib plus chemotherapy.

    Time frame: Through study completion (approximately 2 years)

07

Study locations

8 of 90 sites recruiting
  • Ascentage Investigative Site #1044
    Birmingham, Alabama 35233, United States
    Not yet recruiting
  • Ascentage Investigative Site #1062
    Duarte, California 91010, United States
    Not yet recruiting
  • Ascentage Investigative Site #1134
    Los Angeles, California 90048, United States
    Not yet recruiting
  • Ascentage Investigative Site #1059
    Los Angeles, California 90095, United States
    Not yet recruiting
  • Ascentage Investigative Site #1142
    Miami, Florida 33155, United States
    Not yet recruiting
  • Ascentage Investigative Site #1045
    Augusta, Georgia 30912, United States
    Not yet recruiting
  • Ascentage Investigative Site #1158
    Indianapolis, Indiana 46202, United States
    Not yet recruiting
  • Ascentage Investigative Site #1069
    Indianapolis, Indiana 46237, United States
    Not yet recruiting
  • Ascentage Investigative Site #1084
    Lexington, Kentucky 40536, United States
    Not yet recruiting
  • Ascentage Investigative Site #1064
    Hackensack, New Jersey 07601, United States
    Not yet recruiting
  • Ascentage Investigative Site #1098
    New Brunswick, New Jersey 08901, United States
    Not yet recruiting
  • Ascentage Investigative Site #1160
    Stony Brook, New York 11794, United States
    Not yet recruiting
  • Ascentage Investigative Site #1151
    The Bronx, New York 10461, United States
    Not yet recruiting
  • Ascentage Investigative Site #1501
    Houston, Texas 77030, United States
    Not yet recruiting
  • Ascentage Investigative Site #1806
    Seattle, Washington 98104, United States
    Not yet recruiting
  • Ascentage Investigative Site #1155
    Morgantown, West Virginia 26506, United States
    Not yet recruiting
  • Royal North Shore Hospital
    St Leonards, New South Wales, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Alfred Health
    Melbourne, Victoria 3004, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Royal Perth Hospital
    Perth, Washington 6000, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The First Affiliated Hospital of Bengbu Medical School
    Bengbu, Anhui 233000, China
    Not yet recruiting
    • Yanli Yang, M.D. · Contact
    • Yanli Yang, M.D. · Principal investigator
  • Xinqiao Hospital of Army Medical University
    Chongqing, Chongqing Municipality 214426, China
    Recruiting
    • Cheng Zhang, M.D. · Contact
    • Cheng Zhang, M.D. · Principal investigator
  • Guangdong Province People's Hospital
    Guangdong, Guangzhou 510080, China
    Recruiting
    • Jianyu Weng, M.D. · Contact
    • Jianyu Weng, M.D. · Principal investigator
  • Nanfang Hospital of Southern Medical University
    Guangdong, Guangzhou 510515, China
    Recruiting
    • Hongsheng Zhou, M.D. · Contact
    • Hongsheng Zhou, M.D. · Principal investigator
  • Henan Cancer Hospital
    Zhengzhou, Henan 450003, China
    Recruiting
    • Xudong Wei, M.D. · Contact
    • Xudong Wei, M.D. · Principal investigator
  • Wuhan Union Hospital of Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
    Recruiting
    • Mei Hong, M.D. · Contact
    • Mei Hong, M.D. · Principal investigator
  • The First Affiliated Hospital of Suzhou University
    Suzhou, Jiangsu 215006, China
    Recruiting
    • Suning Chen, M.D.,Ph.D. · Contact
    • Suning Chen, M.D.,Ph.D. · Principal investigator
  • Shanghai Jiao Tong University School of Medicine Ruijin Hospital
    Shanghai, Shanghai Municipality 200025, China
    Not yet recruiting
    • Weili Zhao, M.D.,Ph.D. · Contact
    • Weili Zhao, M.D.,Ph.D. · Principal investigator
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610044, China
    Recruiting
    • Yu Wu, M.D. · Contact
    • Yu Wu, M.D. · Principal investigator
  • Institute of Blood Transfusion of Chinese Academy of Medical Sciences
    Tianjin, Tianjin Municipality 215127, China
    Recruiting
    • Ying Wang, M.D. · Contact
    • Ying Wang, M.D. · Principal investigator
  • Ascentage Investigative Site #8647
    Brno, 62500, Czechia
    Not yet recruiting
  • Ascentage Investigative Site #6305
    Hradec Králové, 50005, Czechia
    Not yet recruiting
  • Ascentage Investigative Site #6304
    Ostrava, 70852, Czechia
    Not yet recruiting
  • Ascentage Investigative Site #6302
    Prague, 10034, Czechia
    Not yet recruiting
  • Ascentage Investigative Site #6309
    Prague, 12800, Czechia
    Not yet recruiting
  • Ascentage Investigative Site #5020
    Le Chesnay, 78150, France
    Not yet recruiting
  • Ascentage Investigative Site #5021
    Lyon, 69008, France
    Not yet recruiting
  • Ascentage Investigative Site #5013
    Nantes, 44000, France
    Not yet recruiting
  • Ascentage Investigative Site #5025
    Nice, 06200, France
    Not yet recruiting
  • Ascentage Investigative Site #5019
    Pessac, 33604, France
    Not yet recruiting
  • Ascentage Investigative Site #5024
    Pierre-Bénite, 69495, France
    Not yet recruiting
  • Ascentage Investigative Site #5022
    Poitiers, 86021, France
    Not yet recruiting
  • Ascentage Investigative Site #5018
    Toulouse, 31059, France
    Not yet recruiting
  • Ascentage Investigative Site #5538
    Bologna, 40138, Italy
    Not yet recruiting
  • Ascentage Investigative Site #5529
    Meldola, 47014, Italy
    Not yet recruiting
  • Ascentage Investigative Site #5539
    Milan, 20132, Italy
    Not yet recruiting
  • Ascentage Investigative Site #5533
    Monza, 20900, Italy
    Not yet recruiting
  • Ascentage Investigative Site #5540
    Ravenna, 48121, Italy
    Not yet recruiting
  • Ascentage Investigative Site #5531
    Roma, 00138, Italy
    Not yet recruiting
  • Ascentage Investigative Site #5550
    Torino, 10126, Italy
    Not yet recruiting
  • Ascentage Investigative Site #5536
    Varese, 21100, Italy
    Not yet recruiting
  • Ascentage Investigative Site #6503
    Bucharest, 020125, Romania
    Not yet recruiting
  • Ascentage Investigative Site #6502
    Cluj-Napoca, 400015, Romania
    Not yet recruiting
  • Ascentage Investigative Site #6507
    Craiova, 200143, Romania
    Not yet recruiting
  • Ascentage Investigative Site #6504
    Iași, 700483, Romania
    Not yet recruiting
  • Ascentage Investigative Site #6602
    Singapore, 119074, Singapore
    Not yet recruiting
  • Ascentage Investigative Site #6603
    Singapore, 169608, Singapore
    Not yet recruiting
  • Ascentage Investigative Site #6604
    Singapore, 308433, Singapore
    Not yet recruiting
  • Ascentage Investigative Site #8206
    Busan, 49201, South Korea
    Not yet recruiting
  • Ascentage Investigative Site #8207
    Busan, 49241, South Korea
    Not yet recruiting
  • Ascentage Investigative Site #8201
    Seoul, 03080, South Korea
    Not yet recruiting
  • Ascentage Investigative Site #8202
    Seoul, 05505, South Korea
    Not yet recruiting
  • Ascentage Investigative Site #8203
    Seoul, 06591, South Korea
    Not yet recruiting
  • Ascentage Investigative Site #8208
    Uijeongbu-si, 11759, South Korea
    Not yet recruiting
  • Ascentage Investigative Site #6018
    Badalona, 08916, Spain
    Not yet recruiting
  • Ascentage Investigative Site #6019
    Badalona, 08916, Spain
    Not yet recruiting
  • Ascentage Investigative Site #6020
    Barcelona, 08035, Spain
    Not yet recruiting
  • Ascentage Investigative Site #6048
    Cáceres, 10003, Spain
    Not yet recruiting
  • Ascentage Investigative Site #6016
    Madrid, 20834, Spain
    Not yet recruiting
  • Ascentage Investigative Site #6049
    Madrid, 20840, Spain
    Not yet recruiting
  • Ascentage Investigative Site #6035
    Madrid, 28006, Spain
    Not yet recruiting
  • Ascentage Investigative Site #6013
    Madrid, 28007, Spain
    Not yet recruiting
  • Ascentage Investigative Site #6011
    Madrid, 28041, Spain
    Not yet recruiting
  • Ascentage Investigative Site #6021
    Santander, 39008, Spain
    Not yet recruiting
  • Ascentage Investigative Site #6050
    Seville, 41010, Spain
    Not yet recruiting
  • Ascentage Investigative Site #6017
    Valencia, 6017, Spain
    Not yet recruiting
  • Ascentage Investigative Site #9201
    Ankara, 06100, Turkey (Türkiye)
    Not yet recruiting
  • Ascentage Investigative Site #9204
    Ankara, 06170, Turkey (Türkiye)
    Not yet recruiting
  • Ascentage Investigative Site #9212
    Ankara, 06200, Turkey (Türkiye)
    Not yet recruiting
  • Ascentage Investigative Site #9209
    Ankara, 06560, Turkey (Türkiye)
    Not yet recruiting
  • Ascentage Investigative Site #9205
    Antalya, 07025, Turkey (Türkiye)
    Not yet recruiting
  • Ascentage Investigative Site #9203
    Istanbul, 34381, Turkey (Türkiye)
    Not yet recruiting
  • Ascentage Investigative Site #9202
    Izmir, 35100, Turkey (Türkiye)
    Not yet recruiting
  • Ascentage Investigative Site #9211
    Kayseri, 38039, Turkey (Türkiye)
    Not yet recruiting
  • Ascentage Investigative Site #9208
    Mersin, 33200, Turkey (Türkiye)
    Not yet recruiting
  • Ascentage Investigative Site #9220
    Samsun, 55139, Turkey (Türkiye)
    Not yet recruiting
  • Ascentage Investigative Site #9210
    Tekirdağ, 59030, Turkey (Türkiye)
    Not yet recruiting
  • Ascentage Investigative Site #7002
    Birmingham, B15 2GW, United Kingdom
    Not yet recruiting
  • Ascentage Investigative Site #7034
    Glasgow, G12 0YN, United Kingdom
    Not yet recruiting
  • Ascentage Investigative Site #7019
    London, SW3 6JJ, United Kingdom
    Not yet recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Dec 2027, 52 months after the start.

Of 59 phase 3 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 86 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 104. This study's planned 52 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2023
First posted
Sep 22, 2023
StartActual
Aug 31, 2023
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jun 30, 2029
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06051409
Collaborators
Guangzhou Healthquest Pharma Co., Ltd
Responsible party
Sponsor
First posted
Sep 22, 2023
Start date
Aug 31, 2023
Primary completion
Dec 31, 2027 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Apr 30, 2026

Study contacts

Ascentage Clinical Operations
Contact
clinical-trials@ascentage.com
301-291-5658
Elias Jabbour, M.D.
principal investigator · M.D. Anderson Cancer Center
Weili Zhao, M.D., Ph.D.
principal investigator · Shanghai Jiaotong University School of Medicine Ruijin Hospital
Suning Chen, M.D., Ph.D.
principal investigator · First Affiliated Hospital of Suzhou Medical College

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olverembatinib

Start the discussion